As most of you know my son Jacob has been dealing with DMD since he was 4. Well we keep getting news and all of it bad I'm just wondering when does the bad news stop and we get some good news. 

On our last visit to the doctor it went as it usually does except for the fact that he had been sick for over a month. And the doctor cant explain why so we are having to wait a month to see a specialist for his lungs because they think they are to weak to fight a common cold. He is still…

We are just two days away from probably my favorite holiday. And I am writing a message to you, like I always do, in my little home office in Middletown before I leave town for Thanksgiving.

I am surrounded by photos of my family and normally would spend a few moments feeling nostalgic. Chris and Patrick permeate every corner of the house, and for…

PPMD is proud to announce a collaboration with Santhera Pharmaceuticals on a benefit/risk study that will focus specifically on patient and caregiver preferences regarding pulmonary therapies in the disease, and will be based on data from Santhera’s successful phase III clinical trial of idebenone. One of the recommendations in our community’s…

If I were to tell you that it takes an average of 10 years and one billion dollars to yield a single new therapy – would you be surprised? Probably not, yet none of us has that luxury of time or money.

If I were to share that many of our nation’s leaders admit that our scientific and clinical institutions and the…

Great news... House and Senate Leadership continue to hear from the disability community that the Achieving a Better Life Experience (ABLE) Act (S. 313/H.R. 647) must pass this year!

The ABLE Act amends Section 529 of the U.S. Tax Code that allows families to save for the future of their child with a…

PPMD and other leaders in the rare disease community were asked by PhRMA to participate in a blog conversation about how to advance the science of…

Kennedy Krieger Institute in Baltimore, Maryland was named a Certified Duchenne Care Center by Parent Project Muscular Dystrophy (PPMD), the leading advocacy organization working to end…

At the Action Duchenne meeting in London on Saturday, Pfizer Inc. announced that it has completed a study in healthy volunteers with its antibody-based therapeutic to block the muscle protein myostatin, and is preparing to start recruitment for a phase II study in Duchenne this month. Watch…

The lungs require the strength of many muscles to help a person to breathe and cough. As people with Duchenne grow older, the respiratory muscles, like the skeletal muscles, become weaker. Like the heart, every person with Duchenne will have pulmonary issues of some type.

The goal of pulmonary care is to allow both the prevention and management of…

The FDA is listening and has told us as much. But that doesn’t mean we should stop doing everything we can to educate the Agency.

Thanks to the dozens of you who participated in PPMD’s benefit/risk project and took the time to share your story, we have been able to compile your responses and will be providing the FDA with…